-
D646251-50mgD-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK .In VitroD-JNKI-1 (AM-111: 1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells. MCE has not independently confirmed the accuracy of these
-
D646251-5mgD-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK .In VitroD-JNKI-1 (AM-111: 1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells. MCE has not independently confirmed the accuracy of these
-
D649990-10mgD4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1 , 3b-hydroxysteroid dehydrogenase ( 3βHSD ) and steroid-5a-reductase ( SRD5A ) and also an antagonist of androgen receptor .In VitroD4-abiraterone (D4A )
-
D649990-25mgD4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1 , 3b-hydroxysteroid dehydrogenase ( 3βHSD ) and steroid-5a-reductase ( SRD5A ) and also an antagonist of androgen receptor .In VitroD4-abiraterone (D4A )
-
D649990-5mgD4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1 , 3b-hydroxysteroid dehydrogenase ( 3βHSD ) and steroid-5a-reductase ( SRD5A ) and also an antagonist of androgen receptor .In VitroD4-abiraterone (D4A )
-
D656087-1mlD4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1 , 3b-hydroxysteroid dehydrogenase ( 3βHSD ) and steroid-5a-reductase ( SRD5A ) and also an antagonist of androgen receptor .In VitroD4-abiraterone (D4A )
-
D649398-10mgDA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. DA 3003-2 has the potential for the research of
-
D649398-25mgDA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. DA 3003-2 has the potential for the research of
-
D649398-5mgDA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. DA 3003-2 has the potential for the research of
-
D650009-100mgDAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.Target:PBRin vitro: DAA1106 binding to PBR was significantly increased in widespread
-
D650009-10mgDAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.Target:PBRin vitro: DAA1106 binding to PBR was significantly increased in widespread
-
D650009-25mgDAA1106 is a potent and selective ligand for peripheral benzodiazepine receptor (PBR), as a potent and selective agonist at the peripheral benzodiazepine receptor.Target:PBRin vitro: DAA1106 binding to PBR was significantly increased in widespread